Alkermes Plc (ALKS)

23.27
NASDAQ : Health Technology
Prev Close 24.28
Day Low/High 22.76 / 24.17
52 Wk Low/High 21.29 / 46.98
Avg Volume 1.29M
Exchange NASDAQ
Shares Outstanding 156.90M
Market Cap 3.81B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes Demonstrates Commitment To Local Community For 11th Consecutive Year With Largest Volunteer Event In Company History

Alkermes Demonstrates Commitment To Local Community For 11th Consecutive Year With Largest Volunteer Event In Company History

WALTHAM, Mass., July 1, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that for the 11 th consecutive year, employees took a day out of the office to roll up their sleeves and volunteer with community organizations across the Greater...

Alkermes Advances ALKS 4230 Into Monotherapy Expansion Phase Of ARTISTRY-1 In Patients With Renal Cell Carcinoma Or Melanoma

Alkermes Advances ALKS 4230 Into Monotherapy Expansion Phase Of ARTISTRY-1 In Patients With Renal Cell Carcinoma Or Melanoma

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage --

Alkermes To Present New Data From Mental Health Portfolio At The American Society Of Clinical Psychopharmacology 2019 Annual Meeting

Alkermes To Present New Data From Mental Health Portfolio At The American Society Of Clinical Psychopharmacology 2019 Annual Meeting

-- New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA® and INVEGA SUSTENNA® in Patients With Schizophrenia --

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FWONA, FWONK, HMN Downgrades: AAME, ABEV, ABR, ALKS, CCS, EXP, PKE, PTR, SCSC, SILC, SMLP, SNMP, TR, TSE Initiations: LAZY, VXRT Read on to get TheStreet Quant Ratings' detailed report:

Alkermes To Present At The UBS Global Healthcare Conference

Alkermes To Present At The UBS Global Healthcare Conference

DUBLIN, May 14, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson, will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, May 20, 2019 at...

Alkermes To Showcase Leadership In Schizophrenia With New Data Presentations At Upcoming Scientific Conferences

Alkermes To Showcase Leadership In Schizophrenia With New Data Presentations At Upcoming Scientific Conferences

-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings --

Alkermes Plc Reports First Quarter 2019 Financial Results

Alkermes Plc Reports First Quarter 2019 Financial Results

-- First Quarter Revenues of $223.1 Million, Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Product Net Sales --

Alkermes Appoints Industry Veteran C. Todd Nichols As Senior Vice President Of Sales And Marketing

Alkermes Appoints Industry Veteran C. Todd Nichols As Senior Vice President Of Sales And Marketing

DUBLIN, April 24, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that C.

Alkermes To Host Conference Call To Discuss First Quarter 2019 Financial Results

Alkermes To Host Conference Call To Discuss First Quarter 2019 Financial Results

DUBLIN, April 18, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.

Alkermes Announces Positive Topline Results From Innovative Study Of ARISTADA® And INVEGA SUSTENNA® For The Treatment Of Schizophrenia

Alkermes Announces Positive Topline Results From Innovative Study Of ARISTADA® And INVEGA SUSTENNA® For The Treatment Of Schizophrenia

-- Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study --

Alkermes Announces Departure Of Jim Robinson

Alkermes Announces Departure Of Jim Robinson

DUBLIN, April 8, 2019 /PRNewswire/ --  Alkermes plc  (Nasdaq: ALKS) announced today that Jim Robinson, President and Chief Operating Officer, has resigned from his position and will leave the company, effective April 19, 2019, for personal reasons.

Alkermes Expands Awards Program With Focus On Advancing Research In Schizophrenia

Alkermes Expands Awards Program With Focus On Advancing Research In Schizophrenia

-- The Second Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program Will Provide Funding for Up To Eight Research Projects With Individual Grant Amounts of Up To $100,000 per Project --

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in...

Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 39th Annual Health Care Conference

Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 39th Annual Health Care Conference

DUBLIN, March 5, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, Mar.

Alkermes Initiates Clinical Study Of ALKS 4230 Administered Subcutaneously In Patients With Advanced Solid Tumors

Alkermes Initiates Clinical Study Of ALKS 4230 Administered Subcutaneously In Patients With Advanced Solid Tumors

-- Once-Weekly and Once-Every-Three-Week Dosing of ALKS 4230 to be Evaluated as Monotherapy and in Combination With Pembrolizumab --

Alkermes To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Alkermes To Present At The 8th Annual SVB Leerink Global Healthcare Conference

DUBLIN, Feb. 20, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABC, ALKS, AUY, BY, CCS, CXO, DVN, HGV, IESC, KRG, OMF, VRNT Downgrades: ARR, CTG, JAZZ, PTN, ROX Initiations: LBRT, NINE Read on to get TheStreet Quant Ratings' detailed report:

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

-- Combinations of ALKS 4230 with Rucaparib and Lucitanib to be Evaluated in Multiple Preclinical Tumor Models --

Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2018 And Provides Financial Expectations For 2019

Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2018 And Provides Financial Expectations For 2019

-- Record Revenues of $1.09 Billion in 2018, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales --

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Alkermes Plc, Inc. (ALKS)

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Alkermes Plc, Inc. (ALKS)

Law Offices of Howard G. Smith reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, Inc.

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2018 Financial Results

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2018 Financial Results

DUBLIN, Feb. 7, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.

Alkermes Receives Complete Response Letter From U.S. Food And Drug Administration For ALKS 5461 New Drug Application

Alkermes Receives Complete Response Letter From U.S. Food And Drug Administration For ALKS 5461 New Drug Application

DUBLIN, Feb. 1, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors With $100K In Losses Of Important February 25th Deadline - ALKS

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors With $100K In Losses Of Important February 25th Deadline - ALKS

NEW YORK, Jan. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ: ALKS) from February 17, 2017...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes Plc To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

TheStreet Quant Rating: D (Sell)